Atezolizumab and hyaluronidase (Tecentriq Hybreza)

General information

Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.
Route: SC

Toxicity management

• Immunotherapy toxicity management

Diseases for which it is established

See Atezolizumab (Tecentriq)

History of changes in FDA indication

• 2024-09-12: Initial approval for all the adult indications as the intravenous formulation of atezolizumab. (Based on IMscin001)

Also known as

• Generic name: atezolizumab and hyaluronidase-tqjs
• Brand name: Tecentriq Hybreza